港交所(00388.HK)任命資產拓展聯席主管
港交所(00388.HK)宣布,任命羅子文(Robert Cheeseman)為董事總經理及市場拓展部資產拓展聯席主管。
羅子文將與聯席主管俞泰碩帶領部門推展香港交易所主要的市場結構項目,進一步提高香港交易所市場的吸引力。羅子文會集中拓展集團的衍生產品市場,加速衍生產品業務增長。羅子文將於下月1日履新,將向市場拓展聯席主管鮑海潔及董凱文(Kevin Rideout)匯報。
羅子文此前任職於瑞士信貸集團,擔任董事總經理兼亞太區主要衍生產品服務主管。他於2018年加入瑞士信貸集團前,在摩根士丹利和高盛的衍生產品部門擔任多個領導職務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.